Zealand Pharma A/S. 

$10.19
109
+$2.44+31.48% Monday 20:00

Statistics

Day High
10.68
Day Low
7.75
52W High
70.16
52W Low
7.75
Volume
400
Avg. Volume
9
Mkt Cap
728.74M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.38
4.82
11.02
17.22
Expected EPS
-1.3785530886
Actual EPS
N/A

Financials

70.23%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
2.9BRevenue
2.04BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ZLDPY. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk is a leading global healthcare company that competes with Zealand Pharma in the diabetes and obesity drug markets, areas where Zealand Pharma also operates.
Sanofi
SNY
Mkt Cap124.45B
Sanofi is a large pharmaceutical company that competes with Zealand Pharma in the development of treatments for diabetes and cardiovascular diseases.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly is a major player in the pharmaceutical industry, competing with Zealand Pharma in the diabetes care sector, particularly in the development of GLP-1 receptor agonists.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca competes with Zealand Pharma in several areas, including the development of new treatments for diabetes and other metabolic disorders.
Merck
MRK
Mkt Cap214.76B
Merck is a global healthcare company that competes with Zealand Pharma in the diabetes sector, particularly in the development of novel therapeutics.
Medicinova
MNOV
Mkt Cap81.42M
MediciNova is involved in the development of novel therapeutics for diseases with unmet medical needs, overlapping with Zealand Pharma's focus areas.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company that has a broad range of products competing in the diabetes and cardiovascular markets, overlapping with Zealand Pharma's focus areas.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb operates in multiple therapeutic areas including cardiovascular diseases, directly competing with some of Zealand Pharma's therapeutic development areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes with Zealand Pharma in the development of treatments for cardiovascular diseases, among other areas.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is involved in creating transformative medicines for people with serious diseases, competing with Zealand Pharma's innovative approach to drug development.

About

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S was incorporated in 1997 and is based in Søborg, Denmark.
Show more...
CEO
Mr. Adam Sinding Steensberg M.D.
Employees
424
Country
DK
ISIN
US98920Y1064

Listings

0 Comments

Share your thoughts

FAQ

What is Zealand Pharma A/S. stock price today?
The current price of ZLDPY is $10.19 USD — it has increased by +31.48% in the past 24 hours. Watch Zealand Pharma A/S. stock price performance more closely on the chart.
What is Zealand Pharma A/S. stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Zealand Pharma A/S. stocks are traded under the ticker ZLDPY.
What is Zealand Pharma A/S. market cap?
Today Zealand Pharma A/S. has the market capitalization of 728.74M
When is the next Zealand Pharma A/S. earnings date?
Zealand Pharma A/S. is going to release the next earnings report on May 07, 2026.
What were Zealand Pharma A/S. earnings last quarter?
ZLDPY earnings for the last quarter are -0.93 USD per share, whereas the estimation was -1.26 USD resulting in a +26.16% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Zealand Pharma A/S. revenue for the last year?
Zealand Pharma A/S. revenue for the last year amounts to 2.9B USD.
What is Zealand Pharma A/S. net income for the last year?
ZLDPY net income for the last year is 2.04B USD.
How many employees does Zealand Pharma A/S. have?
As of April 03, 2026, the company has 424 employees.
In which sector is Zealand Pharma A/S. located?
Zealand Pharma A/S. operates in the Health Care sector.
When did Zealand Pharma A/S. complete a stock split?
Zealand Pharma A/S. has not had any recent stock splits.
Where is Zealand Pharma A/S. headquartered?
Zealand Pharma A/S. is headquartered in Søborg, DK.